Poniard Pharmaceuticals, Inc. (PARD)

OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Aug 5, 2025, 8:00 PM EDT
Market Cap150.00
Revenue (ttm)n/a
Net Income (ttm)-16.23M
Shares Out1.50M
EPS (ttm)-3.79
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume7
Average Volume3
Open0.0001
Previous Close0.0001
Day's Range0.0001 - 0.0001
52-Week Rangen/a
Beta-62.52
RSI99.25
Earnings Daten/a

About Arcadium Lithium

Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplatin in the second-line treatment of patients with small cell lung cancer; Phase II trials evaluating picoplatin as a first-line treatment of metastatic ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1984
Employees 8
Stock Exchange OTCMKTS
Ticker Symbol PARD
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.